Healthlead Public Company Limited

Healthy Lead Public Company Limited, or HL, is preparing to expand into the pet health products market to capture the Pet Humanization trend, as pet owners increasingly treat their pets as family members. Supakorn Panthukanon, Chief Executive Officer of HL, said the company will source and distribute products in the supplement, vitamin, and pet medication categories to meet rising demand from pet owners, and as another channel to extend its customer base and create long-term growth opportunities. This move into the Pet Health market is part of HL's strategy to expand its health product portfolio, after the company accelerated business expansion in the second half of 2026 through both adding distribution channels and developing new products. Most recently, the company opened a new iCare branch on Phutthamonthon Sai 4 to increase service space and expand its customer base, while continuing to develop innovative products under the Prime brand, including Prime Immuliv, Prime G3, as well as products that enhance the absorption of key active ingredients, or Bioavailability Enhancers, and products in the skincare group. Meanwhile, herbal products under the Q brand have won international awards, reflecting its approach to product development aimed at expanding the product portfolio and adding diversity to the business. The company views the pet health market as having growth potential in line with the Pet Humanization trend, which is leading pet owners to spend more on healthcare, disease prevention, and improving their pets' quality of life. It is therefore another market that HL plans to use as a base to extend revenue and create future growth opportunities.

Healthlead Public Company Limited, or HL, is preparing to launch its Telepharmacy platform through an application operated by iCare Health Company Limited, aiming to elevate pharmacies into the digital era. Patients will be able to consult pharmacists remotely and receive medications delivered to their homes, in accordance with regulations permitted by the Food and Drug Administration (FDA). Additionally, HL has partnered with pharmaceutical delivery service CERO Win to support logistics, enhancing service standards. This development marks a significant step in integrating technology into the Health & Wellness business, with expectations for it to serve as a growth engine driving revenue in 2026 to a new record high, in line with targets.

HL is confident that its Q3/2026 performance will recover from the previous quarter, after the burden of provisions and asset depreciation from the closure of 5 branches, worth 5.42 million baht, has ended. Meanwhile, consumer purchasing power is improving, and the COVID-19 outbreak is boosting sales of ATK test kits. The company is also moving forward with expanding new branches, driving this year's performance to grow over last year. Mr. Supakorn Phantukanon, Chief Executive Officer of Healthlead Public Company Limited (HL), revealed that the company is confident its operating results in Q3/2026 will improve from Q2/2026, as there will be no recognition of depreciation and provisions for asset depreciation from the closure of a total of 5 branches, worth a total of 5.42 million baht, as in the previous quarter. As a result, this Q3 will start to see better recovery. In addition, there are signs of recovery in consumer spending, which tends to improve. Meanwhile, government support factors, such as the "Thai Helps Thai Plus" project, are expected to help stimulate consumption and benefit the business in the long term. Although some consumers choose to use services from stores outside the tax system, the company views that such impact can be offset by the benefits of spending stimulus measures and should not significantly affect the overall business. Regarding the COVID-19 outbreak situation, it continues to positively impact ATK test kit sales, which have increased slightly but not as high as the previous period, as public concern has decreased. However, the company has continuously prepared products and equipment to meet customer demand in this segment. The company continues to expand branches in potential locations. Most recently, it opened a new pharmacy, iCare Phutthamonthon Sai 4, which has received good response and is expected to generate satisfactory sales. However, in Q3, HL expects to open about 1 new branch, while in Q4/2026, it is considering locations to support the opening of about 1-2 more new branches, with an investment budget of about 5 million baht per branch, focusing on the suitability of locations and revenue-generating potential. As for the full-year performance target, the company admits that its results may not meet the original target. However, it still expects that the overall business will be able to achieve growth compared to last year. It is also accelerating operational efficiency improvements while motivating the team to work at full potential under challenging goals, to drive performance for the rest of the year and build a foundation for continuous growth in the future.

Health Lead Public Company Limited, or HL, has launched the dietary supplement Prime Immuliv, which contains extracts of dandelion, schisandra, quercetin, L-cysteine, B vitamins, and various plant extracts, to penetrate the health market. The company is also expanding its pharmacy network, opening a Pharmax branch at Tha Tien Market in the second quarter of 2026 and preparing to open an iCare branch at Bang Yai Market in early third quarter of 2026, alongside developing more than 20 new innovative herbal products. Chief Executive Officer Supakorn Phanthukanont expects the new product launch and branch expansion to support sales and company growth in the second half of the year.